Nanopublication

< Home

ID

http://purl.org/np/RAQpp12qzkzqBMsz2q-vYLAf5nTBPkT9aS4OjjAwA-E3U

Formats

.trig | .trig.txt | .jelly | .jelly.txt

Content

@prefix this: <http://purl.org/np/RAQpp12qzkzqBMsz2q-vYLAf5nTBPkT9aS4OjjAwA-E3U> .
@prefix sub: <http://purl.org/np/RAQpp12qzkzqBMsz2q-vYLAf5nTBPkT9aS4OjjAwA-E3U#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix pav: <http://purl.org/pav/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0026767> a biolink:DiseaseOrPhenotypicFeature;
    rdfs:label "COVID-19";
    biolink:category biolink:DiseaseOrPhenotypicFeature .
  
  sub:_1 a biolink:Association;
    rdf:object <http://purl.obolibrary.org/obo/MONDO_0026767>;
    rdf:predicate biolink:treats;
    rdf:subject <file:///app/bamlanivimab>;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94b996dc-ddc4-41ce-9a9f-3d91cb187473> .
  
  sub:_2 a biolink:Association;
    rdf:object <http://purl.obolibrary.org/obo/MONDO_0026767>;
    rdf:predicate biolink:treats;
    rdf:subject <file:///app/bamlanivimab>;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94b996dc-ddc4-41ce-9a9f-3d91cb187473> .
  
  sub:_3 a biolink:Association;
    rdf:object <file:///app/bamlanivimab>;
    rdf:predicate biolink:interacts_with;
    rdf:subject <file:///app/Etesevimab>;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94b996dc-ddc4-41ce-9a9f-3d91cb187473> .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2022-10-13T13:46:07.779203"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-3668-2627;
    prov:wasQuotedFrom " Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing. This combination regimen is also used for post-exposure prophylaxis of COVID-2019 in unvaccinated or immunocompromised adults." .
  
  biolink: pav:version "2.3.0" .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB";
    npx:hasSignature "Nwm+TCfPueg/dGV/alO9K7tT3DhhzIfpBJDy2D4i5o644+Zf9imi0TddHr1zvReNVhdCV4cSlesHS74yeeiCaZ+UrSA5v9xUQ2FIW8RBuWH1BXnNfoDhzzZ0qfOn4LWTojvgC3SCd5BqhhbxVRLEwN56zoZ6hDugQ0UeNcFFc10+3O0LrFFsLMvWIODzjPyX3XLRIpGti0Wmsf5WrCLkIS3MAyu4aMxqK/kueJV68nsdI6poCFopqxpnSZSewdYea/JznU6zc+KZrJvTB1swL8MiPozfBe4h01Y5AIdC1aKynFCDh0vDA4ushOBpSn2XdUJheQ5saNdsJYs8PKSk2A==";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2022-10-13T13:46:07.779203"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-3668-2627 .
}